Flagship-backed Generate Biomedicines shares fall 6% in Nasdaq debut
27/02/2026 17:53
Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' GENB.O shares fell 6.25% in its Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market volatility kept investors cautious toward new listings. (Reporting by Pragyan Kalita in Bengaluru; Editing by Sahal Muhammed) ((Pragyan.Kalita@thomsonreuters.com;))
Recent news on Generate Biomedicines
See all newsZealand Pharma, Generate strike AI obesity drug deal worth up to $1.2 billion (updated)
Brief: Generate Biomedicines And Zealand Pharma Enter Collaboration And License Agreement To Develop Protein Therapeutics Engineered With Ai For Metabolic Diseases
Zealand Pharma, Generate strike obesity drug deal worth up to $1.2 billion, Bloomberg News reports
Brief: Zealand Pharma Makes Deal With Generate Worth Up To $1.2 Billion - Bloomberg News
Brief: Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial Of ‘Armored’ Car T Therapy For Ovarian Cancer